search
Back to results

Moxonidine Effects on Neuropeptide Y

Primary Purpose

Obesity, Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Moxonidine
Sponsored by
Aristotle University Of Thessaloniki
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring hypertension, obesity, Neuropeptide Y, moxonidine

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy

Exclusion Criteria:

  • age beyond 25-75 years,
  • not taking currently anti-hypertensive medication
  • not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Group

    Arm Description

    0.6 mg moxonidine daily

    Outcomes

    Primary Outcome Measures

    serum Neuropeptide Y levels
    ELISA
    systolic blood pressure
    mmHg
    diastolic blood pressure
    mmHg

    Secondary Outcome Measures

    Weight
    kg
    Body Mass Index
    kg/m2
    Total Cholesterol
    mg/dl
    HDL Cholesterol
    mg/dl
    LDL Cholesterol
    mg/dl
    Serum triglycerides
    mg/dl

    Full Information

    First Posted
    November 18, 2021
    Last Updated
    November 24, 2021
    Sponsor
    Aristotle University Of Thessaloniki
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05147753
    Brief Title
    Moxonidine Effects on Neuropeptide Y
    Official Title
    Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    January 11, 2010 (Actual)
    Primary Completion Date
    June 30, 2014 (Actual)
    Study Completion Date
    June 30, 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Aristotle University Of Thessaloniki

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension
    Detailed Description
    Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Obesity, Hypertension
    Keywords
    hypertension, obesity, Neuropeptide Y, moxonidine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    90 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Group
    Arm Type
    Experimental
    Arm Description
    0.6 mg moxonidine daily
    Intervention Type
    Drug
    Intervention Name(s)
    Moxonidine
    Intervention Description
    0.6 mg moxonidine daily
    Primary Outcome Measure Information:
    Title
    serum Neuropeptide Y levels
    Description
    ELISA
    Time Frame
    12 weeks
    Title
    systolic blood pressure
    Description
    mmHg
    Time Frame
    12 weeks
    Title
    diastolic blood pressure
    Description
    mmHg
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Weight
    Description
    kg
    Time Frame
    12 weeks
    Title
    Body Mass Index
    Description
    kg/m2
    Time Frame
    12 weeks
    Title
    Total Cholesterol
    Description
    mg/dl
    Time Frame
    12 weeks
    Title
    HDL Cholesterol
    Description
    mg/dl
    Time Frame
    12 weeks
    Title
    LDL Cholesterol
    Description
    mg/dl
    Time Frame
    12 weeks
    Title
    Serum triglycerides
    Description
    mg/dl
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy Exclusion Criteria: age beyond 25-75 years, not taking currently anti-hypertensive medication not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eleni Karlafti, MD, PhD
    Organizational Affiliation
    AHEPA University Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Moxonidine Effects on Neuropeptide Y

    We'll reach out to this number within 24 hrs